SPECIAL ISSUE

WILEY

Endocrine surgery in the Coronavirus disease 2019 pandemic: Surgical Triage Guidelines

Yelda Jozaghi MD ¹ Mark E. Zafereo MD ¹ Nancy D. Perrier MD ²
Jennifer R. Wang MD ¹ Elizabeth Grubbs MD ² Neil D. Gross MD ¹
Sarah Fisher MD ² Erich M. Sturgis MD ¹ Ryan P. Goepfert MD ¹
Stephen Y. Lai MD ¹ Conor Best MD ³ Naifa L. Busaidy MD ³
Maria E. Cabanillas MD ³ Ramona Dadu MD ³ Robert F. Gagel MD ³
Mouhammed A. Habra MD ³ Mimi I. Hu MD ³ Camilo Jimenez MD ³
Steven I. Sherman MD ³ Sonali Thosani MD ³ Jeena Varghese MD ³
Steven G. Waguespack MD ³ Steven Weitzman MD ³ Anita K. Ying MD ³
Paul H. Graham MD ²

Correspondence

Mark E. Zafereo, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit FCT 10.6008, Houston, TX 77030. Email: mzafereo@mdanderson.org

Abstract

Background: In the face of the COVID-19 pandemic, cancer care has had to adapt rapidly given the Centers for Disease Control and Prevention and the American College of Surgeons (ACS) issuing recommendations to postpone nonurgent surgeries.

Methods: An institutional multidisciplinary group of Head and Neck Surgical Oncology, Surgical Endocrinology, and Medical Endocrinology devised Surgical Triaging Guidelines for Endocrine Surgery during COVID-19, aligned with phases of care published by the ACS.

Results: Phases of care with examples of corresponding endocrine cases are outlined. Most cases can be safely postponed with active surveillance, including most differentiated and medullary thyroid cancers. During the most acute phase, all endocrine surgeries are deferred, except thyroid tumors requiring acute airway management.

Conclusions: These guidelines provide context for endocrine surgery within the spectrum of surgical oncology, with the goal of optimal individualized multidisciplinary patient care and the expectation of significant resource diversion to care for patients with COVID-19.

KEYWORDS

coronavirus, COVID, endocrine, guideline, surgery

Yelda Jozaghi and Mark E. Zafereo are co-first authors.

¹Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas

²Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas

³Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas

Facing the realities of the coronavirus disease 2019 (COVID-19) pandemic, governments around the world and in the United States have implemented societal interventions such as "social distancing" measures, "stay at home" orders, border closures, and nationwide lockdowns. The underlying goal is to curtail all nonessential population movement in an attempt to limit the rate of spread of this virus. Similar measures have been undertaken in the medical community to prioritize patient encounters to those necessitating timely evaluation and treatment.

Several populations are considered to be at higher risk of complications of a COVID-19 infection. These include immunocompromised patients such as those undergoing active or recent oncologic treatment. Mortality rates among patients with cancer have been reported to be 29%. In a nationwide analysis of COVID-19 cases in China, patients with cancer were noted to have a 39% rate of severe events as compared with 8% in the noncancer population. These severe events included intensive care unit (ICU) admissions requiring ventilation or death.

Cancer care has had to adapt rapidly to the evolving pandemic and accommodate the particular vulnerability of the oncologic patient population to COVID-19. In March 2020, both the Centers for Disease Control and Prevention and the American College of Surgeons (ACS) issued recommendations to postpone or cancel elective surgeries.³ Increasingly, hospitals have been forced to reallocate resources to the care of the critically ill. The ACS later expanded on their recommendations to triage various oncologic surgeries based on each hospital's COVID-19 preponderance and availability of local resources, which they divide into three phases of care. 4,5 The National Comprehensive Cancer Network has highlighted the unique challenges of cancer care during this time and has encouraged the coordination of organizational structures to facilitate the collaborative, thoughtful care of patients with cancer.⁶

Several large subspecialty societies have recently published surgical guidelines for the care of patients with endocrine tumors during the COVID-19 pandemic.7-10 In addition, many medical centers and academic institutions have developed their own clinical practice guidelines to triage oncologic patient care. In preparation for the pandemic, The University of Texas MD Anderson Cancer Center has established multidisciplinary endocrine surgery guidelines and initiated specific conferences to determine case urgency. As a multidisciplinary group consisting of Head and Neck Surgical Oncology, Surgical Endocrinology, and Medical Endocrinology, we have devised the following Surgical Triaging Guidelines for Endocrine Surgery at the time of a pandemic such as COVID-19. These guidelines apply specifically to surgical procedures. Other adjuvant therapies, particularly postoperative radioactive iodine ablation, may also be safely deferred in the context of this pandemic.

We have aligned the case priorities to the phases of care outlined by the ACS and have triaged case acuity based on the ACS Elective Surgery Acuity Scale. 11 Phases of care with added examples of corresponding endocrine cases have been provided. According to the listed acuity descriptions, most cases (including the majority of differentiated thyroid carcinoma) can be safely postponed with active surveillance. These guidelines provide a context for endocrine surgery within the entire spectrum of surgical oncology, especially when overall priorities may focus on ensuring available personal protective equipment, ICU resources, and adequate protection of medical personnel during the COVID-19 pandemic. Although these recommendations are intended to serve as general principles, we continue to advocate that, where possible, surgeries be considered individually in a multidisciplinary setting based on the unique patient and environment circumstances.

1 | PROPOSED ENDOCRINE SURGERY TRIAGING ALGORITHM ALIGNED WITH THE AMERICAN COLLEGE OF SURGEONS PHASES OF CARE

1.1 | Phase I

Few COVID-19 patients, hospital resources not exhausted, institution still has ICU ventilator capacity and COVID-19 trajectory not in rapid escalation phase.

Surgery restricted to patients likely to have survivorship compromised if surgery not performed within next 3 months.

Surgical cases that need to be performed as soon as feasible:

- · Thyroid cancer requiring acute airway management
- Resectable anaplastic or poorly differentiated thyroid cancer without *BRAFV600E* mutation*
- Progressive/clinically aggressive differentiated or medullary thyroid cancer
- Large suspected thyroid malignancy with documented progression
- Large goiters with significant symptomatic airway compression**
- Suspected parathyroid carcinoma with significant symptomatic hypercalcemia
- Suspected adrenocortical carcinoma
- Medically uncontrolled hyperfunctioning endocrine tumors

Surgical cases that can be safely deferred:

· Differentiated thyroid cancer***

- Medullary thyroid cancer***
- Indeterminate thyroid nodules without documented progression
- · Thyroid goiters**
- · Primary hyperparathyroidism
- Medically controlled hyperfunctioning endocrine tumors
- Incidental, nonfunctional adrenal lesions

*Patients with anaplastic thyroid cancer with *BRAFV600E* mutations should be offered BRAF/MEK inhibitor therapy initially, and surgery can be deferred.¹²

**Generally, mildly symptomatic airway compression from large goiters is subacute or chronic and does not require immediate intervention. Very rarely, a patient may present with significant and acute airway compromise, in which case surgery or airway intervention cannot be safely postponed.

***Most differentiated and medullary thyroid cancers are slow-growing tumors that do not cause significant morbidity over the short term, although there is a subset of more biologically aggressive cancers that progress more rapidly. Therefore, clinical correlation with rate of progression (if known), size, invasiveness of surrounding structures, and proximity to critical structures is recommended.

1.2 | Phase II

Many COVID-19 patients, ICU and ventilator capacity limited, and/or operating room supplies limited.

Surgery restricted to patients likely to have survivorship compromised if surgery not performed within next few days.

Surgical cases that need to be performed as soon as feasible:

- Thyroid cancers requiring acute airway management
- Resectable anaplastic or rapidly progressive poorly differentiated thyroid cancer without BRAFV600E mutation*
- Rapidly progressive/clinically aggressive differentiated or medullary thyroid cancers*
- · Rapidly progressive adrenocortical carcinoma
- Medically uncontrolled hyperfunctioning endocrine tumors
- Suspected parathyroid cancer with significant hypercalcemia refractory to medical management

All other endocrine diagnoses can generally be deferred.

*Some anaplastic, poorly differentiated, and advanced progressive differentiated and medullary cancers require major surgery such as laryngectomy, tracheal resection, and/or sternotomy. These more advanced and complex cases should be considered in alignment with available hospital resources.

1.3 | Phase III

Hospital resources are all routed to COVID 19 patients, no ventilator or ICU capacity, OR supplies exhausted.

Surgery restricted to patients likely to have survivorship compromised if surgery not performed within next few hours

Surgical cases that need to be performed as soon as feasible:

· Thyroid cancer requiring acute airway management

All other endocrine diagnoses are deferred.

Alternative treatment approaches for endocrine neoplasia for which surgical intervention is deferred due to COVID-19 pandemic:

- Most surgeries for thyroid nodules, thyroid goiters, differentiated thyroid cancers, and medullary thyroid cancers and adrenal nodules can be safely deferred without need for medical therapy
- Consider TSH suppression for differentiated thyroid cancers
- Anaplastic, poorly differentiated, or progressive/ advanced differentiated and medullary thyroid cancers with targetable mutations may be candidates for targeted systemic therapy
- Optimize medical management of hyperfunctioning endocrine tumors (thyroid, parathyroid, and adrenal)
- Coordination of care with other health care providers/ facilities according to resource availability and travel restrictions

ORCID

Yelda Jozaghi https://orcid.org/0000-0002-1933-5746 *Jennifer R. Wang* https://orcid.org/0000-0002-0807-3832

Erich M. Sturgis https://orcid.org/0000-0002-1069-4822

Ryan P. Goepfert https://orcid.org/0000-0002-3291-841X

Maria E. Cabanillas https://orcid.org/0000-0002-5124-

REFERENCES

 Zhang L, Zhu F, Xie L, Wang C, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. *Ann Oncol*. 2020. https://doi.org/10.1016/j.annonc.2020.03.296.

- 2. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. *Lancet Oncol.* 2020;21(3):335-337.
- 3. Sealander KS, Dombey D, Rogers A, Miller M, Madhani S. *How to Handle Elective Surgeries and Procedures During the COVID-19 Pandemic*. McDermott Will and Emery; 2020. https://www.mwe.com/insights/how-to-handle-elective-surgeries-and-procedures-during-the-covid-19-pandemic/. Accessed April 1, 2020.
- American College of Surgeons, Commission on Cancer. COVID-19 Guidelines for Triage of Colorectal Cancer Patients. American College of Surgeons; 2020. https://www.facs.org/covid-19/clinicalguidance/elective-case/colorectal-cancer. Accessed April 1, 2020.
- American College of Surgeons, Commission on Cancer. COVID-19 Guidelines for Triage of Thoracic Patients. American College of Surgeons; 2020 https://www.facs.org/covid-19/clinical-guidance/ elective-case/thoracic-cancer. Accessed April 1, 2020.
- Ueda M, Martins R, Hendrie PC, et al. Managing cancer care during the COVID-19 pandemic: agility and collaboration toward a common goal. *J Natl Compr Canc Netw.* 2020;18(4): 366-369.
- 7. Stack B, Randolph G. Endocrine Surgery during the Covid-19 Pandemic. American Head and Neck Society; 2020. https://www.ahns.info/wp-content/uploads/2020/03/Endocrine-Surgery-during-the-Covid.pdf. Accessed April 3, 2020.
- 8. Givi B, Schiff BA, Chinn SB, et al. Safety recommendations for evaluation and surgery of the head and neck during the COVID-

- 19 pandemic. *JAMA Otolaryngol Head Neck Surg.* 2020. https://doi.org/10.1001/jamaoto.2020.0780.
- Society of Surgical Oncology. Resource for Management Options of Endocrine/Head and Neck Cancer During COVID-19. Bristol, UK: Society of Surgical Oncology; 2020. https://www.surgonc. org/wp-content/uploads/2020/03/Endocrine-Head-and-Neck-Resource-during-COVID-19-3.30.20.pdf. Accessed April 3, 2020.
- American Association of Endocrine Surgeons. https://www. endocrinesurgery.org/. Accessed April 3, 2020.
- American College of Surgeons. COVID-19: Guidance for Triage of Non-Emergent Surgical Procedures. American college of surgeons; 2020. https://www.facs.org/covid-19/clinical-guidance/triage. Accessed April 1, 2020.
- 12. Wang JR, Zafereo ME, Dadu R, et al. Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAFV600E-mutated anaplastic thyroid carcinoma. *Thyroid*. 2019;29(8):1036-1043.

How to cite this article: Jozaghi Y, Zafereo ME, Perrier ND, et al. Endocrine surgery in the Coronavirus disease 2019 pandemic: Surgical Triage Guidelines. *Head & Neck.* 2020;42: 1325–1328. https://doi.org/10.1002/hed.26169